iqwig-symposium kosten-nutzen-bewertung: modelling in ...€¦ · general introduction to clinical...
TRANSCRIPT
Modelling in IQWiG's Cost-Benefit Assessment
Uwe Siebert, MD, MPH, MSc, ScD1,2
Professor of Public Health (UMIT)Assoc. Professor of Radiology (Harvard Univ.)
1 Chair, Dept. of Public Health, Medical Decision Making and HTA,UMIT - University of Health Sciences, Medical Informatics, and
Technology, Hall/Innsbruck, Austria2 Director, Cardiovascular Research Program, MGH Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA
2
Overview
1. General introduction to clinical and economic decision-analytic modeling
2. The role of decision-analytic modeling in IQWiG's cost-benefit assessments
3. Challenges
What is a model?
4
Definition Model IThe International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research Practices – Modeling Studies:
"[...] an analytic methodology that accounts for events over time and across populations, that is based on data drawn from primary and/or secondary sources, and whose purpose is to estimate the effects of an intervention on valued health consequences and costs."
[Weinstein et al., Value in Health 2003]
5
Definition Model IIU.S. National Research Council:
Simulation model = "[...] a replicable, objective sequence of computations used for generating estimates of quantities of concern [...]"
[National Research Council, 1991]
6
Definition Model IIIBuxton and colleagues defined models in scientific disciplines:
"Models [...] are a way of representing the complexity of the real world in a more simple and comprehensible form"
[Buxton, Health Economics. 1997]
7
Purposes of Modeling in Economic Evaluation
[Siebert, Eur J Health Econom 2003]
8
Purposes of Modeling in Economic Evaluation
1. Combining evidence from short-term clinical trials and long-term epidemiological studies
2. Assessment of screening programs and diagnostic procedures
3. Extrapolating efficacy beyond the time horizon of a clinical trial
4. Generalizing from efficacy to routine effectiveness
5. Transferring the evidence from one health care system or country to another
6. Resource allocation7. Considering patient
preferences8. Informing decisions in the
absence of clinical trial data
9. Fine-tune technologies10. Value-of-information
analysis11. Health policy models and
national projections12. Health technology
assessment[Siebert, Eur J Health Econom 2003]
Decision-Analytic Modeling
10
Goals of Decision Analysis (DA)
I. Selecting the "optimal strategy" after balancing medical benefits, risks and costs of different alternatives
II. The process of decision analysis makes structure, elements, and parameters of the decision problem explicit and transparent; accessible for discussion
11
Definition DA
• Decision analysis is a systematic, explicit and quantitative approach for decision making under uncertainty
• Synonyms / similar terms: – decision-analytic modeling, decision modeling,
mathematical modeling, pharmacoeconomic modeling, simulation
12
Clinical DA
Natural course of disease
Therap./diag. efficacy
Life expectancy
To treat or not to treat?To test or not to test?To screen or not to screen?Which treatment, test, or screening strategy?
Decision
Ethics
Policy
Risk, Side effects
Quality of life
13
Economic DA
Natural course of disease
Therap./diag. efficacy
Life expectancy
Costs
To treat or not to treat?To test or not to test?To screen or not to screen?Which treatment, test, or screening strategy?
Decision
Ethics
Policy
Risk, Side effects
Quality of life
14
Examples for Decision Problems• Diagnostic tests
– sensitivity vs. specificity• Treatment
– efficacy vs. side effects• Life expectancy vs. quality of life
– e.g., chemotherapy in advanced cancer• Costs vs. health affects
– societal willingness-to-pay• Risk preference
– risk-averse vs. risk-seeking• further ...
Tradeoffs
15
The decision must be made
16
The Decision-Analytic Framework• Precise research question• Target population• Alternatives (strategies)• Perspective• Time horizon• Health states, events, other elements• Outcomes: e.g. response, clinical status, major
adverse events, life expectancy, QALYs, costs, cost-effectiveness
• Model type: e.g. decision tree, Markov model, DES• Analysis: cohort simulation, microsimulation• Basecase and sensitivity analysis
17
Model Types
Decision analysis uses probabilistic models to analyze primary and/or secondary data
• Decision trees• Markov models• Discrete event simulation• Transmission models• Agent-based models• Further …
18
Response
No ResponseTreat
Response
No ResponseWait and see
Response
No ResponseNo Treat
Patient or Population
p1
1-p1
p2
1-p2
p3
1-p3
Decision Tree
19
Response
No ResponseTreat
Response
No ResponseWait and see
Response
No ResponseNo Treat
Patient or Population
p1
1-p1
p2
1-p2
p3
1-p3
ER LE QALY C
ER LE QALY C
ER LE QALY C
ER LE QALY C
ER LE QALY C
ER LE QALY C
Consequences
Decision Tree
20
Markov Model: Bubble Diagram
Well Disease
Death
Chronic Disease
21
Markov Model: Bubble Diagram
Well Disease
Death
Chronic Disease
22
Markov Model: Bubble Diagram
Well Disease
Death
p = 1.00
p = 0.65 p = 0.60p = 0.30
p = 0.05 p = 0.40
Chronic Disease
23
Markov Model: Bubble Diagram
Well Disease
Death
p = 1.00
p = 0.65 p = 0.60p = 0.30
p = 0.05 p = 0.40
U=1 U=0.6
U=0
Chronic Disease
24
Markov Model: Bubble Diagram
Well Disease
Death
p = 1.00
p = 0.65 p = 0.60p = 0.30
p = 0.05 p = 0.40
U=1 U=0.6
U=0
Costs€2000
Chronic Disease
25
Markov Trace
Well Disease DeadStart
Cumulative Costs, LE, QALYs
26
Markov Trace
Well Disease Dead
0.650.30 0.05
0.60 1.000.40
after 1 year after 1 year:Cost, LE, QALYs
Well Disease DeadStart
Cumulative Costs, LE, QALYs
27
Markov Trace
Well Disease Dead
0.650.30 0.05
0.60 1.000.40
after 1 year after 1 year:Cost, LE, QALYs
Well Disease DeadStart
Well Disease Dead
etc.
after 2 years
0.650.30 0.05
0.60 1.000.40
After 2 years:Costs, LE, QALYs
Cumulative Costs, LE, QALYs
28
Comparing Different Strategies
Clinical and economic weighting
Without Intervention
WellU=1
DiseaseU=0.6
DeathU=0
0.65 0.60
1.00
0.30
0.05 0.40
Without Intervention
WellU=1
DiseaseU=0.6
DeathU=0
0.65 0.60
1.00
0.30
0.05 0.40
WellU=1
DiseaseU=0.6
DeathU=0
0.65 0.60
1.00
0.30
0.05 0.40
With Intervention
WellU=1
Disease U=0.6
DeathU=0
0.75 0.60
1.00
0.10
0.15 0.40
Intervention costs: 20.000 €With Intervention
WellU=1
Disease U=0.6
DeathU=0
0.75 0.60
1.00
0.10
0.15 0.40
With Intervention
WellU=1
Disease U=0.6
DeathU=0
0.75 0.60
1.00
0.10
0.15 0.40
WellU=1
Disease U=0.6
DeathU=0
0.75 0.60
1.00
0.10
0.15 0.40
Intervention costs: 20.000 €
29
Markov-Trace
Without interventionWithout
preventionCycle z
WellU1=1Pz(G)
DiseaseU2=0,6Pz(K)
DeathU3=0Pz(T)
Cycle-Effect.
(QALY)
Cumulat.Effect.
(QALY)
Cycle-Cost(€)
Cumulat.Cost(€)
0 1.000 0.000 0.000
1 0.650 0.300 0.050 0.830 1.830 600 600
2 0.423 0.375 0.203 0.648 1.478 750 1350
3 0.275 0.352 0.374 0.486 1.963 704 2054
... ... ... ... ... ... ... ...
19 0.000 0.001 0.998 0.001 3.141 3 4281
20 0.000 0.000 1.000 0.000 3.141 0 4281
Sum 2.857 2.140 16.003 3.141 4281
30
Cumulat. Effectiveness(QALY)
Cumulat. Cost (€)
Without intervention 3.141 4.281
With intervention 3.582 21.983
Increments (differences) 0.441 17.703
Incremental cost-utility ratio = €17703/0.441 QALY = €40099/QALY
Comparing Different Strategies
31
Discrete Event Simulation (DES)
• Entities (Patients)
• Attributes (Characteristics of patients)
• Events, Processes (Relapse, hosp., surgery)
• Resources (Staff, facilities, devices)
• Variables (not tied to entity, e.g. discount rate)
• Time (Start and end of simulation, warm up)
32
Model Taxonomy
[Brennan et al., 2006]
33
Decision-analytic models are an aid
-- not a complete procedure --
to decision makers
Modelling in IQWiG's Cost-Benefit Assessment
35
Rationale of Modeling Costs
Economic data from RCTs not sufficient to inform decisions– study environment modifies practice– not transferable– no information on long-term consequences– may not be available at all
⇒ Modeling economic outcomes is an essential component of comprehensive economic evaluations
36
Rationale of Modeling Costs
Intervention Clinical Outcome
Long-term Health
Resources Costs
37
Purpose of Economic Modeling in IQWiG
• Assess efficiency (Wirtschaftlichkeit) of a technology and provide firm basis for decisions on reasonableness of reimbursement and pricing
• a) provide value for x-axis of EF– for y-axis, use health outcome from IQWiG's clinical
benefit assessment (EbM-based)– health outcomes must be modeled in IQWiG's
economic models to generate valid cost estimates• b) estimate budget impact
– see BIA
38
Specific Purposes of Modeling in the IQWiG Framework
• y-axis:– estimate complete economic consequences– model beyond trial time horizon– combine different data sources– perform indirect comparisons in absence of head-to-head trials– project cost over time, budget impact
• x-axis:– usually no modeling, use of empirical clinical benefit measure– combining benefit and harm, transferring benefit to cardinal
scale, or linking valid surrogates to patient-relevant outcomes may involve modeling
• General:– Assess different scenarios, uncertainty, value of information &
suggest further research priorities
39
IQWiG's Modeling Requirements1. Full transparence
– structure, input parameters, assumptions2. Sufficient depth
– adequate representation of disease, intervention effects and costs
3. Flexibility– multiple assumptions, scenarios, settings
4. Ability to assess uncertainty– structural and parameter uncertainty
5. Validity– rigorous peer review
6. Specificity for German health care context– demographics, epidemiology, practice patterns, costs
40
Modeling Process
Model development Validation Analysis Reporting
41
10 Steps1. Define precise research question2. Develop graphical model representation3. Collect input parameters4. Define functional relationships5. Choose modeling technique6. Program model7. Validate model8. Perform analysis9. Report results10. Critically discuss and interpret results
42
1. Define precise research question (PICO)
• Population & subgroups• Intervention of interest• Comparators• Outcomes (cost categories)
43
2. Develop graphical model representation
• relevant components (patient characteristics, natural history of disease, intervention, outcomes)
• links (causal and statistical associations)• analytic structure• benefit measure as pre-defined by IQWiG• present concept to expert panel (clinicians,
methodologists)
44
3. Collect input parameters• systematic search for published and other
available data, different sources:– RCTs for treatment effect– observational cohort studies for natural history of disease
and long-term mortality– pharmacoepidemiologic studies for safety– cross-sectional studies and registries for routine resource
use and costs (cost data from RCTs have low relevance)• quality assessment• transformations, adaptations, standardizations,
deflation• additional targeted data acquisition (e.g., from
registries, new studies)
45
4. Define functional relationships
• functional relation: outcome = f(determinants)• determinants: pat. characteristics, intervention,
compliance, time, setting, etc.• different types:
– stratified data– prediction scores– regression functions (linear, logistic, Cox, mixed, two-
step, etc.)– others
CAVE: causality, may need to use causal epidemiologic methods (g-estimation, MSM)
46
5. Choose modeling techniqueIQWiG has no a-priori preference for modeling
technique, choice depends on research question
• Decision tree• Markov model• Discrete event simulation (DES) • Transmission model• Agent-based model (ABM)• others
Currently, DES and ABM underused in health economics, powerful tools
47
6. Program model
• no suggested software• complete documentation• electronic version of the model
48
7. Validate model• face validity: expert panel, peer-review• technical verification: debugging• internal validation: check with input parameters• external validation: check with independent data• cross-validation: compare with other models
(structure/parameters/results)
CAVE: heterogeneous quality of published models!Expert panel: clinical, epidemiologic, statistical,
decision-analytic, public health, economic, etc.
49
8. Perform analysis
• relevant scenarios• subgroup analyses• uncertainty analysis (1-way, multi-way, PSA)
50
9. Report results
• clear and complete description of framework, methods, model, and rationale for choice of technique (no standard format)
• description of assumptions and input data with sources/references
• validation techniques and results• basecase, subgroups, uncertainty
assessment/sensitivity analyses• electronic version of the model (protection of IPR)
51
10. Critically discuss and interpret results
• interpret EF and describe cost-effectiveness (EF zone)
• discuss budget impact • limitations• potential bias: direction and magnitude• uncertainty assessment• further research recommendations, value of
further information
52
IQWiG's Mandatory Features"Minimum set of requirements"
a) Model framework– perspective– time horizon– duration of treatment– discounting
b) Model quality– appropriate depth– justification of modeling technique
CAVE: Minimum set of requirements = necessary (but not sufficient) for good model quality
53
a) Model Framework• Economic study type
– cost-effectiveness study using EF approach• Perspective
– community of German citizens insured by the SHI– costs to statutory health care system, includes cost for
patient such as out-of-pocket costs, etc.• Time horizon
– sufficient to cover extent of illness, capture all costs affected by technology
– for many chronic diseases: lifetime• Duration of treatment
– as in trial vs. German practice• Discounting
– discount costs, sensitivity analysis on discount rate
54
b) Model Quality
• Appropriate depth– all aspects of disease impacting costs (& health)– benefits and harms– heterogeneity– German practice patterns– real world (e.g., reduced compliance)– short-term and long-term costs– different subgroups, settings, regions, scenarios
• Justification of modeling technique
Challenges
56
Challenges• Several legal and regulatory "givens" restrict modeling options• Modeling approaches differ across agencies/countries need
international modeling reference case?• Predictability for manufacturers?• Simplicity vs. validity• Modeling restricted to economic evaluation and only economic
outcomes• Need experience with "German approach", then refine IQWiG's
modeling guidelines• Policy impact unclear (rationale decision vs. political/market-
driven decisions)• Ethical considerations (utilitarism vs. equity principles)• Need for experienced modelers, modeling education
57
Decision-analytic models are an aid
-- not a complete procedure --
to decision makers
58www.smdm.org
Want to hear more about modeling?